Start/CI

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze CI in workspace
CINYSE/health care

The Cigna Group

$304.50Up+11.04 (+3.76%)
Research reviewed: 12. Juli 2026, 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

The Cigna Group operates in Managed Health Care within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

시가
295.75
고가
305.25
저가
294.88
시가총액
805.5억
PER
12.91
52주 최고가
--
배당
2.130%
분기 배당금
--

3-month price context

Das Chart zeigt den jüngsten 3-Monats-Trend, damit Nutzer die kurzfristige Struktur verstehen können, bevor sie den vollen Workspace öffnen.

Investment thesis

Base case
Specialty pharmacy, care services and benefit-management scale can deepen relationships with health-plan clients. The base case remains conditional on pbm policy change staying manageable.
Bull case
Specialty pharmacy, care services and benefit-management scale can deepen relationships with health-plan clients. Growth in complex therapies can increase demand for specialty distribution, pharmacy and adherence services. Strong cash generation can support repurchases and debt reduction when operating targets are met.
Bear case
New rules on rebates, spread pricing or transparency could reduce benefit-management profitability. Loss or repricing of large health-plan and employer contracts can create meaningful revenue volatility. Unexpected utilization can pressure the healthcare segment despite underwriting discipline.
Thesis invalidation
Reassess the thesis if new rules on rebates, spread pricing or transparency could reduce benefit-management profitability.

Key catalysts

  • Evernorth growth

    Specialty pharmacy, care services and benefit-management scale can deepen relationships with health-plan clients.

  • Specialty medicines

    Growth in complex therapies can increase demand for specialty distribution, pharmacy and adherence services.

  • Capital returns

    Strong cash generation can support repurchases and debt reduction when operating targets are met.

Principal risks

  • PBM policy change

    New rules on rebates, spread pricing or transparency could reduce benefit-management profitability.

  • Client concentration and retention

    Loss or repricing of large health-plan and employer contracts can create meaningful revenue volatility.

  • Medical-cost execution

    Unexpected utilization can pressure the healthcare segment despite underwriting discipline.

Latest earnings research

Q1 2026

The Cigna Group's first-quarter 2026 results reflected continued Evernorth pharmacy and health-services growth alongside disciplined execution in Cigna Healthcare and active capital returns.

Valuation interpretation

  • Evernorth's recurring service model supports cash generation, but policy durability is central to the multiple.
  • Capital returns should be judged after allowing for client retention, medical-cost volatility and regulatory investment.

Peer research

UNHELVABBV

Recent news

StockStory · 2시간 전

Why Cigna (CI) Stock Is Up Today

Trefis · 8시간 전

The Premium On CVS Stock Vs What Its Peers Deliver

Trefis · 4일 전

UNH Showered Owners With Cash. The Stock Did Not Cooperate

Barchart · 4일 전

What to Expect From Cigna's Next Quarterly Earnings Report

Trefis · 5일 전

The Real Price Of UnitedHealth Stock Isn't On Today's Label

Zacks · 7일 전

UnitedHealth Bets on Profitability Over Growth: Will It Pay Off?

Data and research sources

Research updated: 12. Juli 2026, 00:00 UTC
3 verified sources
The Cigna Group Reports First Quarter 2026 ResultsThe Cigna Group · earningsVerified

Fetched: 12.7.2026, 0:00:00 UTC

Published: 1.5.2026, 00:00:00

Open original source
The Cigna Group Investor RelationsThe Cigna Group · companyVerified

Fetched: 12.7.2026, 0:00:00 UTC

Open original source
The Cigna Group SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 12.7.2026, 0:00:00 UTC

Published: 1.5.2026, 00:00:00

Open original source

Continue in the research workspace

Keep CI in context, run a multi-agent analysis, and monitor thesis changes.

Analyze CI free

Das gesamte Research-System erkunden

Jede Phase erfüllt eine klare Aufgabe und hinterlässt ein prüfbares Ergebnis.

AnalysemethodikMarktberichte lesenAktien erkunden

Continue researching this stock

Marktanalyst

Marktanalyst fokussiert sich innerhalb von Kernresearch auf die Phase Beobachten und bereitet den Kontext für nachgelagerte Rollen vor.

Fundamentalanalyst

Fundamentalanalyst fokussiert sich innerhalb von Kernresearch auf die Phase Beobachten und bereitet den Kontext für nachgelagerte Rollen vor.

Nachrichtenanalyst

Nachrichtenanalyst fokussiert sich innerhalb von Kernresearch auf die Phase Beobachten und bereitet den Kontext für nachgelagerte Rollen vor.

Risikomanager

Risikomanager fokussiert sich innerhalb von Risiko und Monitoring auf die Phase Überwachen und bereitet den Kontext für nachgelagerte Rollen vor.